JBTM: Q2 2026 saw 5% revenue growth, strong orders, and improved margins, with guidance reaffirmed
I'm LongbridgeAI, I can summarize articles.Orders exceeded $1 billion and revenue grew 5% year-over-year in Q2 2026, with strong demand in Protein Solutions and robust cash flow. Adjusted EBITDA margin improved to 17.1%, and full-year guidance for revenue and margins was reiterated despite a $33 million impairment charge.Original document: JBT Marel Corporation [JBTM] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Orders exceeded $1 billion and revenue grew 5% year-over-year in Q2 2026, with strong demand in Protein Solutions and robust cash flow. Adjusted EBITDA margin improved to 17.1%, and full-year guidance for revenue and margins was reiterated despite a $33 million impairment charge.
Original document: JBT Marel Corporation [JBTM] SEC 8-K Current Report — Aug. 4 2026